U.S., Oct. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07212023) titled 'Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed KMT2Ar or NUP98r AML (REVEAL-ND KMT2A)' on Sept. 30.
Brief Summary: The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with acute myeloid leukemia (AML) with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding revumenib to chemotherapy
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Acute Myeloid Leukemia
Intervention:
DRUG: Revumenib
Participants will receive revumenib orally.
DRUG: Intensive Chemotherapy Re...